Company research
TFA Therapeutics, Inc.
CIK 1885680Updated Nov 16, 2026
RAJAF price & chart
Loading TradingView…
OTC:RAJAF on TradingView ↗In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2023 | Q3 2022 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| AssetsUSD | 1,797,722Source | — | 4,657,511Source | 4,623,704Source | 3,351,782Source | 2,104,853Source |
| Property, Plant and Equipment, NetUSD | 1,545,203Source | — | 3,632,901Source | 3,909,599Source | 2,814,766Source | 1,425,135Source |
| Current assets: | ||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 16,911Source | — | 3,199Source | 37,284Source | 23,104Source | 16,100Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | — | — | 305Source | — | 149,510Source |
| Inventory, NetUSD | 4,308Source | — | 674,196Source | — | — | 313,530Source |
| Assets, CurrentUSD | 52,135Source | — | 997,742Source | 601,602Source | 327,175Source | 501,552Source |
| Operating Lease, Right-of-Use AssetUSD | — | — | 13,097Source | 99,328Source | 195,775Source | — |
| Other Assets, NoncurrentUSD | — | — | 13,771Source | 13,175Source | 14,066Source | — |
| LIABILITIES AND EQUITY | ||||||
| LiabilitiesUSD | 1,980,661Source | — | 5,192,062Source | 4,999,247Source | 3,503,578Source | 3,056,187Source |
| Stockholders’ equity: | ||||||
| Common Stock, Value, IssuedUSD | 11,112Source | — | 11,112Source | 11,112Source | 11,112Source | 11,112Source |
| Additional Paid in CapitalUSD | 221,288Source | — | 221,288Source | 221,288Source | 221,288Source | 221,288Source |
| Retained Earnings (Accumulated Deficit)USD | -477,490Source | — | -854,046Source | -699,224Source | -472,966Source | -1,224,575Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 62,151Source | — | 87,095Source | 91,281Source | 88,770Source | 40,841Source |
| Stockholders' Equity Attributable to ParentUSD | -182,939Source | 117,086Source | -534,551Source | -375,543Source | -151,796Source | -951,334Source |
| Liabilities and EquityUSD | 1,797,722Source | — | 4,657,511Source | 4,623,704Source | 3,351,782Source | 2,104,853Source |
| Current liabilities: | ||||||
| Liabilities, CurrentUSD | 1,465,332Source | — | 5,192,062Source | 4,986,645Source | 2,966,143Source | 2,935,130Source |
| Operating Lease, Liability, CurrentUSD | 99,055Source | — | 13,173Source | 87,016Source | 90,091Source | 57,109Source |
| Accounts Payable, CurrentUSD | — | — | 365,140Source | 276,125Source | 185,434Source | 751,135Source |
| Operating Lease, Liability, NoncurrentUSD | 101,329Source | — | — | 12,602Source | 106,356Source | 121,057Source |
| Additional Financial Items | ||||||
| Accrued Liabilities, CurrentUSD | — | — | 85,074Source | 32,410Source | 26,889Source | 62,754Source |
| Long-term Debt, Current MaturitiesUSD | 99,055Source | — | — | — | — | 57,109Source |
| Long-term Debt, Excluding Current MaturitiesUSD | — | — | — | — | 431,079Source | — |
cash flow · annual statements
| Line item | Q4 2023 | Q4 2022 | Q3 2023 | Q3 2022 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 56,757Source | 168,899Source |
| Changes in operating assets and liabilities: | ||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | — | -185,797Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | 358,549Source | — | 192,634Source | -48,833Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 182,849Source | -122,450Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | -42,221Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | -35,845Source | 312,006Source | 359,724Source | -321,378Source |
| Cash flows from investing activities: | ||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | -305,637Source | -319,820Source | -475Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | 349,237Source | 319,487Source | 475Source |
| Cash flows from financing activities: | ||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -32,208Source | 245,787Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | -34,085Source | 14,180Source | 7,004Source | -83,584Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 16,974Source | 19,336Source | 3,199Source | 37,284Source | 23,104Source | 16,100Source |
| Supplemental disclosure of cash flow information: | ||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | 2,185Source | 150Source | — | — |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | 792Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | 1,760Source | 7,811Source | -692Source | -7,518Source |
| Additional Financial Items | ||||||||
| AmortizationUSD | — | — | — | — | 74,017Source | 16,793Source | — | — |
| Amortization of Debt Issuance CostsUSD | — | — | — | — | — | — | 86,216Source | — |
| DepreciationUSD | — | — | — | — | 135,243Source | 407,265Source | 56,757Source | 24,760Source |
| Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of TaxUSD | — | — | — | — | — | — | 865,085Source | — |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | — | — | 4,328Source | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | 2,437,980Source | — |
| General and Administrative ExpenseUSD | — | — | — | — | — | — | 538,554Source | 572,589Source |
| Goodwill and Intangible Asset ImpairmentUSD | — | — | — | — | — | — | — | 1,177Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | — | — | -154,822Source | -226,258Source | 169,285Source | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | 582,324Source | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | 34,957Source | 21,530Source | 792Source |
| Inventory Write-downUSD | — | — | — | — | — | — | — | 84,709Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | — | — | -154,822Source | -226,258Source | 751,609Source | -720,093Source |
| Nonoperating Income (Expense)USD | — | — | — | — | -13,694Source | -7,388Source | 37,018Source | -76,599Source |
| Operating ExpensesUSD | — | — | — | — | 901,869Source | 717,673Source | 538,554Source | 576,030Source |
| Operating Lease, ExpenseUSD | — | — | — | — | 91,310Source | 90,609Source | 81,203Source | — |
| Other Nonoperating Income (Expense)USD | — | — | — | — | 5,485Source | 5,339Source | -37,018Source | -4,855Source |
| Realized Investment Gains (Losses)USD | — | — | — | — | — | — | 865,085Source | — |
income statement · annual statements
| Line item | Q4 2023 | Q4 2022 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 1,245,348Source | 1,253,484Source | 882,533Source | 448,785Source |
| Cost of Goods and Services Sold | — | — | —Source | —Source | —Source | —Source |
| Operating Income (Loss)USD | — | — | -141,128Source | -183,913Source | 227,833Source | -642,702Source |
| Other Nonoperating Income (Expense)USD | — | — | 5,485Source | 5,339Source | -37,018Source | -4,855Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -154,822Source | -191,301Source | 190,815Source | — |
| Income Tax Expense (Benefit)USD | — | — | — | 34,957Source | 21,530Source | 792Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -154,822Source | -226,258Source | 751,609Source | -720,093Source |
| Earnings Per Share, BasicUSD per share | — | — | 0Source | 0Source | 0.01Source | -0.01Source |
| Earnings Per Share, DilutedUSD per share | — | — | 0Source | 0Source | 0.01Source | -0.01Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 111,120,000Source | 111,120,000Source | 111,120,000Source | 104,417,534Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 111,120,000Source | 111,120,000Source | 111,120,000Source | 104,417,534Source |
| Additional Financial Items | ||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | 34,957Source | 21,530Source | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | 168,899Source |
| General and Administrative ExpenseUSD | — | — | — | — | 538,554Source | 572,589Source |
| Gross ProfitUSD | — | — | 760,741Source | 533,760Source | 766,387Source | -66,672Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | -154,822Source | -226,258Source | 169,285Source | — |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | — | — | 0Source | 0Source | 0Source | — |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | — | — | 0Source | 0Source | 0Source | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | 582,324Source | — |
| Interest ExpenseUSD | — | — | — | — | 26,535Source | 71,772Source |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | -19,179Source | -17,055Source | -39,770Source | — |
| Interest Income, OtherUSD | — | — | — | — | 7Source | 28Source |
| Labor and Related ExpenseUSD | — | — | — | — | 109,295Source | 110,938Source |
| Nonoperating Income (Expense)USD | — | — | -13,694Source | -7,388Source | 37,018Source | -76,599Source |
| Operating ExpensesUSD | — | — | 901,869Source | 717,673Source | 538,554Source | 576,030Source |
| Operating Lease, ExpenseUSD | — | — | 91,310Source | 90,609Source | 81,203Source | — |
| Other ExpensesUSD | — | — | — | — | — | 35,690Source |
| Other General and Administrative ExpenseUSD | — | — | 901,869Source | 717,673Source | 193,569Source | — |
| Other IncomeUSD | — | — | — | — | 2,752Source | — |
| Realized Investment Gains (Losses)USD | — | — | — | — | 865,085Source | — |
| Research and Development ExpenseUSD | — | — | — | — | — | 118,444Source |
| Selling ExpenseUSD | — | — | — | — | — | 3,441Source |
Filing attachments
ea030418701ex99-1.htm · 6-K · 2026-09-02
Exhibit 99.1 TFA THERAPEUTICS, INC. (formerly known as Cordyceps Sunshine Biotech Holdings Co., Ltd.) OTCQB: RAJAF PRIVATE PLACEMENT ORDINARY SHARE SUBSCRIPTION AGREEMENT CONFIDENTIAL - INVITATION ONLY; NO PUBLIC DISTRIBUTION OR U.S. DIRECTED SELLING EFFORTS The Shares have not been registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or any state securities law and are offered solely in reliance upon an applicable exemption. Neither the U.S. Securities and Ex…
Read attachment ↗ea029590801ex99-1.htm · 6-K · 2026-06-25
Exhibit 99.1 AntcinA(樟芝酸A)合作發展協議 Cooperation and Development Agreement for the Antcin A Platform 甲方 / Party A 天寵生物研究股份有限公司 乙方 / Party B 英屬開曼群島商天草控股股份有限公司 前言 / Recitals 緣甲方係依據中華民國法律登記設立的公司,乙方係依據英屬開曼群島法律登記設立的公司,甲方同意將其所有 Antcin A(樟芝酸A)平台(以下稱「Antcin A平台」)相關之全球商業化權利、授權權利及資本市場發展權利依據本協議的約定無償授權乙方。本協議目的並非移轉Antcin A平台資產法律所有權,而係建立甲、乙雙方合作發展關係。 第一條 定義 / Definitions Antcin A平台資產包括以樟芝酸A為核心之所有技術、資料、研究成果、法規成果、智慧財產、相關商業化成果及相關衍生權利,包括但不限於全球商業化權利、授權權利及資本市場發展權利;Antcin A平台產品包括但不限於TFA-01及未來衍生產品、改良分子、新適應症、人體用藥…
Read attachment ↗